Most material SEC filings — August 11, 2026

Aether Holdings (via subsidiary Aether Compute LLC) is acquiring 60% of Noviant Inc. for $3.6M enterprise value ($900K cash + $2.7M restricted parent stock). Four Noviant founders (Kevin Wang, Jin Yi Wang, James Mo, Enbo Zeng) are selling their 100% stake. Separately, Aether borrowed $1.62M from Streeterville Capital at 8% interest, secured by IP and assets, with redemption rights and trigger-based balance increases. Target closing August 7, 2026.

Hour Loop, Inc. amended its loan agreement with founders Sam Lai and Sau Kuen Yu on August 10, 2026. Outstanding principal balance stands at $3,410,418 (comprised of $2,060,418 remaining from prior amendments plus $1,350,000 in new advances between April–August 2026). Repayment schedule: $200,000 monthly starting August 31, 2026, with full balance due December 31, 2026; interest accrues at 4.75% annually. This is the fourth amendment since the original September 2021 loan of ~$4.04M.

Eloxx completed a $66.0M underwritten public offering (2,975,000 shares at $11/share plus 3,025,000 pre-funded warrants) in June 2026, netting $58.3M after underwriting costs. The company uplifted to Nasdaq Capital Market (ticker ELOX) and ended Q2 2026 with $62.0M cash, no debt, and stockholders' equity of $46.4M (vs. deficit of $11.9M at year-end 2025). Cash is projected to fund operations through mid-2028 clinical data readouts for exaluren in Alport syndrome (Phase 2b initiating Q3 2026, data mid-2027) and ADPKD (Phase 2 planned 2027, data mid-2028).

3i LP commits up to $9,000,000 in investment ($3M at closing, $6M over two months) under existing Series B/C terms, conditional on due diligence and Nasdaq listing maintenance. Concurrent governance changes: CEO Michael Handley terminated immediately; Chair Sheryle Bolton steps down and becomes Special Advisor; Maier Tarlow becomes Chairman; 3i nominates two additional directors. Investment and governance changes subject to definitive documentation execution.

On May 26, 2026, Olenox Industries Inc. (public market cap ~$7.8M) acquired 100% of CS Digital Ventures LLC, a Bitcoin mining operator, for total consideration of $52.1M comprising: $14.0M in Series D Preferred Stock (140,000 shares at $100/share), $16.0M Seller Note (10% interest, due May 2029), warrants for 1.5M common shares at $5–$9/share exercise prices (valued $6.7M), and up to $15.4M in contingent Earnout Shares tied to revenue and EBITDA milestones. CS Digital operates ~4,684 Antminer S21+ units generating ~$20.6M mining revenue (2025). The acquisition eliminates Olenox's historical $120M+ accumulated deficit by consolidation and creates $21.5M preliminary goodwill. Pro forma 2025 combined net loss: $20.7M; Q1 2026 net loss: $3.6M.

Edible Garden AG (market cap ~$7.7M) entered an Equity Distribution Agreement with Maxim Group LLC on August 11, 2026, authorizing sale of up to $7,195,548 of common stock via at-the-market offering at best national bid prices. Maxim receives 3.0% commission on gross proceeds. The offering is registered under Form S-3 (File No. 333-297912, effective August 7, 2026) and may continue for up to three years or until shares are exhausted.

Aardvark Therapeutics reported Q2 2026 results with critical setbacks: FDA placed a full clinical hold on ARD-101 (its lead program for Prader-Willi Syndrome hyperphagia) in May 2026 following a voluntary pause; the company terminated both Phase 3 HERO and OLE trials in June 2026 and does not intend to resume them as designed. Cash and equivalents stand at $73.9M (down from $91.2M at Q1 2026), funding operations into late 2027. Q2 net loss was $14.4M; R&D spend declined to $10.5M from $13.1M YoY due to trial pause, but G&A rose to $4.6M from $2.7M due to headcount and severance from a June workforce reduction.

RYTHM, Inc. amended its secured convertible notes and warrant agreements with RSLGH, LLC and Vision Management Services, LLC, effective October 10, 2026. The amendment removes all beneficial ownership limitations (49.99% caps) that previously restricted exercise/conversion of: the November 2024 Note ($10M, converted to 3.22M warrant shares in Nov 2025), the May 2025 Note ($27M), the August 2025 Note ($45M), and approximately 9.5M warrant shares issued as interest and service payments. RSLGH is the sole Required Holder of all notes and warrants.

BioXcel Therapeutics amended its credit agreement with Oaktree Fund Administration (lenders) effective immediately. Key changes: (1) New transaction milestone requiring the company to enter definitive agreements by August 21, 2026, for either full debt repayment in cash or an alternative capital solution acceptable to majority lenders; (2) Minimum liquidity requirements reduced from $25M initially to $3M by August 10, 2026; (3) Added three commercial tort claims to collateral (disputes with Cognitive Research, Caitlin Meyer, and Segal Institute). The covenant relaxation signals lenders are accommodating deteriorating liquidity while imposing a hard deadline for a material capital event.

Big Sky Industrial executed a five-year, 100% take-or-pay helium sales agreement on April 27, 2026 with an investment-grade counterparty at $285/Mcf plant-gate price with CPI escalation after March 2028. On April 20, 2026, the company doubled its senior secured credit borrowing base from $10M to $20M at 200 bps over SOFR, maturing May 31, 2029. Phase 1 construction is advancing with $9.6M invested in first half of 2026; commercial operations and first revenue targeted Q1 2027. The company has $21.5M total liquidity as of June 30, 2026.

Bolt Biotherapeutics reported Q2 2026 net loss of $7.7M (vs. $8.6M in Q2 2025) on collaboration revenue of $5K (vs. $1.8M prior year). Cash and equivalents totaled $18.1M as of June 30, 2026, expected to fund operations into Q1 2027. Lead program BDC-4182 Phase 1/2 trial progresses in Cohort 4 (4.0 mg/kg dose); initial clinical data expected with Q3 2026 results. R&D expenses declined to $5.1M from $7.5M YoY following restructuring.

Dermata Therapeutics, a $3.1M market-cap company, announced its strategic pivot from pharmaceutical development to direct-to-consumer skincare is culminating in the August 25, 2026 launch of Tome Foundational Treatment. As of June 30, 2026, the company had $4.4M cash (down from $7.5M at year-end 2025), with $4.9M used in operations during H1 2026 offset by $1.9M in ATM financing. SG&A expenses surged to $2.8M in Q2 2026 from $1.2M in Q2 2025, driven by $0.7M in legal fees and $0.6M in marketing spend; the company expects cash to fund operations into Q4 2026.

Duos Technologies Group completed sale of Duos Technologies, Inc. (DTI), its wholly owned rail inspection subsidiary, to Sandbank Acosta, LLC on August 5, 2026 (effective June 30, 2026). Sale consideration: $1.00 cash to Buyer; Duos funded $3.5M target cash into DTI pre-closing; DTI issued $5.435M promissory note to Duos at 5% interest, due August 5, 2031, with change-of-control acceleration. Duos contributed estimated $56.9M intercompany receivable to DTI as equity pre-closing. Adrian Goldfarb (50% owner of Buyer) was interim DTI President; Javier Acosta (50% owner of Buyer) becomes President. Related-party transaction approved by Board with independent fairness opinion.

10% owner DART KENNETH BRYAN (FLUT) bought 332K shares (~$31.4M) on the open market (1.5% of holdings). Open-market insider purchase — historically a bullish signal.

iSpecimen Inc. settled a dispute with WestPark Capital, Inc. (dated August 6, 2026) by paying $97,500 to resolve an arbitration claim for $269,999.91 arising from engagement agreements dated July 31, 2025 and October 15, 2025. The settlement terminates both the arbitration and the underlying engagement agreements in their entirety, with each party bearing its own legal costs and both parties releasing all claims.

Polar Power, Inc. (public market value ~$3.0M) entered into a Securities Purchase Agreement effective July 29, 2026, to issue 833 shares of Series A Convertible Preferred Stock (stated value $1,000 per share; purchase price 90% of stated value = ~$749.7K per share, total ~$624.7M aggregate, though specific dollar amounts are redacted with bullet symbols in the filing). The purchaser also receives common stock purchase warrants. The deal includes registration rights, a board appointment right for the investor, anti-dilution protections, and restrictions on the company's capital structure. No specific counterparty name is disclosed in this exhibit; filing signatures are redacted. Closing contingent on stockholder approval and SEC registration statement effectiveness.

Director ORBIMED ADVISORS LLC (BRVE) bought 11.1M shares (~$34.9M) on the open market (98% of holdings). Open-market insider purchase — historically a bullish signal.

Director Chimovits Erez (BRVE) bought 11.1M shares (~$34.9M) on the open market (98% of holdings). Open-market insider purchase — historically a bullish signal.

Director BAKER BROS. ADVISORS LP (REPL) bought 2.7M shares (~$33.0M) on the open market (51% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner AH Bio Fund IV, L.P. (BRVE) bought 10.2M shares (~$19.8M) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

On July 2, 2026, Ondas Inc. completed acquisition of High Point UAS, LLC for $200M cash + 39,999,998 shares at closing + 44,999,998 shares due Jan 4, 2027 (total stock consideration ~$674.9M). High Point generated $104.8M revenue and $55.2M gross profit in 2025; posted $11.7M net loss. Pro forma combined 2025 revenue $155.5M, loss $180.9M. Ondas is ~$392M market cap; deal is roughly 2.2x company market value.

On August 11, 2026, Tango Therapeutics registered a prospectus supplement for up to $400 million in common stock (par value $0.001) via an at-the-market (ATM) sales agreement with an unnamed sales agent. The offering is covered by a Form S-3ASR filed November 21, 2025. No shares have been issued yet; this establishes authorization and legal validity subject to future board approval and pricing.

ClearOne Inc. entered into four separate advisor agreements (all dated August 7, 2026, effective June 1, 2026) with First Finance Ltd. (25,000 shares), Betelgeuse Capital Advisors Inc. (90,000 shares), Gang3 Capital Ltd. (140,000 shares), and JJK Holdings Ltd. (600,000 shares). Total: 855,000 shares issued as sole compensation for general advisory services including board participation, network introductions, and contract negotiation assistance. All advisors receive piggyback and demand registration rights. Issuance pending stockholder approval within two days of such approval.

Venture Global reported Q2 2026 revenue of $4.6 billion (48% YoY increase) and net income of $1.3 billion (266% YoY increase). The company raised full-year 2026 Consolidated Adjusted EBITDA guidance to $8.7–9.1 billion from $8.2–8.5 billion, reflecting strong operational performance, 2+ MTPA of new LNG offtake agreements (Atlantic-SEE increased to 1.0 MTPA, new EnBW 0.82 MTPA deal, plus TotalEnergies 0.85 MTPA and Vitol increase to 1.7 MTPA), and refinancings ($2.25B, $1.75B, $1.5B, and $750M debt facilities) generating >$100M in annual cost savings. Dividend increased 122% to $0.04/share; Calcasieu Pass shipped 37 cargos in Q2 despite major maintenance; Plaquemines Phase 1 COD reaffirmed for Q4 2026.

Shattuck Labs completed a $86.2M underwritten public offering and realized $57.1M from warrant exercises (July 2026), boosting cash/investments to $208.3M as of June 30, 2026 versus $50.5M a year prior. The company reports positive Phase 1 data for lead candidate SL-325 (DR3 blocking antibody) showing favorable safety, best-in-mechanism immunogenicity (3.7% antidrug antibodies), and durable blockade supporting quarterly dosing; Phase 2b trial (RECEPTIVE-CD1) in Crohn's disease initiates Q3 2026 with data expected H1 2028. SL-846 (DR3 × IL-23R bispecific) enters Phase 1 in 2027. Runway extends to 2029.

IES Holdings, Inc. (Buyer) agreed to acquire all outstanding shares of DBM Global, Inc. (Company) from parent Innovate Corp. and DBM Global Intermediate Holdco Inc. (Seller) via merger. Consideration consists of Stock Consideration (shares of Buyer Common Stock, amount not specified in excerpt) plus Seller Cash Consideration (amount not specified in excerpt), subject to purchase price adjustment based on closing working capital, cash, and indebtedness. Transaction dated August 7, 2026; Closing contingent on regulatory approvals (HSR, antitrust) and other standard conditions. Agreement includes 338(h)(10) tax elections and $35M tax-related payment to Seller.

On April 30, 2026, Broadwind sold its Abilene, Texas wind fabrication facility to IES Infrastructure for up to $19.5M, completing a strategic exit from wind tower manufacturing. Q2 2026 continuing operations (excluding divested wind/fabrication): revenue $24.3M (+67% YoY), Adjusted EBITDA $1.6M vs. -$1.1M YoY, loss from operations -$0.7M vs. -$3.0M YoY. Orders surged 68% YoY to $35.2M; combined Industrial Solutions and Gearing backlog grew 93% YoY. Cash position strengthened to $31.3M (net of minimum availability) with $6.3M total debt.

Harvard Bioscience (market cap ~$18.2M) completed a $40M debt refinancing with BroadOak Capital Partners consisting of $10M Term Loan A, $22.5M Term Loan B (converts at $10/share), and $7.5M Term Loan C. The refinancing extends maturity to December 2029, reduces annual debt service by $3M, and includes BroadOak board seat and 200K warrant grant. Company appointed new CEO John Duke (July 2025) and permanent CFO Mark Frost (March 2026), and announced Project Viking: consolidating Holliston, MA plant by Q1 2027, targeting $3M adjusted EBITDA improvement in 2027 and $4M ongoing. FY26 guidance raised to 3-5% revenue growth; adjusted EBITDA margin guided 57-59%.

Daniel Vitt's employment terminated August 7, 2026, with severance of ~$946k (base salary for 16.5 months plus 75% of 2026 bonus = $670k lump sum + $276.4k bonus + €18k/month healthcare for 18 months). He transitions to unpaid Founder/Chair of Scientific Advisory Board role with €15k/month consulting agreement (12 months, ≤15 hrs/month). Non-compete and IP restrictions imposed. Simultaneously, Immunic appointed Erik Lundgren as CEO (May 22, 2026), Michael Panzara as Chief Medical Officer (April 24, 2026), Michael Bonney as Board Chair (May 16, 2026), and Elena Ridloff to Board (August 6, 2026). Company has €155.1M cash; Q2 2026 net loss was $34.1M.

CalciMedica completed a private placement financing of approximately $49M (with ~$15M upfront) on June 24, 2026, to advance its pulmonary hypertension program including Auxora Phase 1b trial in PAH and CM5480 IND submission, both anticipated mid-2027. The company also achieved FDA alignment on Phase 2b acute pancreatitis trial design (primary endpoint: reduction in new-onset severe respiratory failure). Cash position: $18.6M as of June 30, 2026; net loss H1 2026: $2.7M ($0.16/share); common shares outstanding increased to 30.7M from 15.4M (99% dilution from capital raise).

Aura Biosciences executed a CEO transition on April 30, 2026: founder Elisabet de los Pinos terminated as CEO and transitioned to a 6-month consulting role with accelerated equity vesting; Natalie Holles hired as new CEO with $700k base salary, 55% bonus target, and ~2.5% equity grant (1.33M options + 367k RSUs) plus 0.5% performance-based RSUs. Simultaneously, the company repurchased up to 6.92M shares (from its $321M market cap) from investor Matrix Capital at the net public offering price, financed by a registered equity offering. The company also increased authorized common shares from 150M to 500M and extended option exercise periods to June 2028.

C4 Therapeutics and Roche entered a new Research Collaboration and License Agreement effective April 8, 2026, replacing their prior 2018 agreement. C4T receives $20M upfront payment plus potential milestone payments (up to ~$385M across three targets based on development and sales), royalties on net sales (tiered 10-15%), and fees for research progression (LIGo/LOGo). Roche gains exclusive worldwide license to C4T's protein degradation technology for degrader-antibody conjugate (DAC) development across three initial targets plus one optional target, with C4T providing research services through preclinical stages before handoff to Roche.

Autolus reported Q2 2026 net product revenue of $45.7 million (vs. $20.9M in Q2 2025), a 119% year-over-year increase driven by AUCATZYL adoption across 82+ U.S. authorized treatment centers and UK market entry. The company raised FY 2026 guidance to $140–$150 million (from $120–$135M). Gross margin improved to 55% in Q2 from 6% in Q1, supported by higher volumes and cost reductions. Autolus secured a five-year, interest-only credit facility of up to $250 million from Perceptive Advisors ($75M funded at close; $25M optionally available; $150M on achievement of revenue milestones), strengthening cash runway to Q2 2028.

In April 2026, Sagimet completed an underwritten equity offering raising $175.0 million in gross proceeds, resulting in cash, equivalents, and marketable securities of $257.6 million as of June 30, 2026. The company stated this funding is expected to support operations through 2028, including completion of a planned Phase 3 clinical trial of denifanstat in moderate to severe acne (800 patients, 2:1 randomization, U.S., initiation targeted for 2H 2026) and NDA submission. Denifanstat previously met all primary and secondary endpoints in a Phase 3 trial in China (480 patients, conducted by partner Ascletis), with NDA accepted by NMPA in December 2025. TVB-3567 (follow-on FASN inhibitor) Phase 1 trial ongoing; Phase 2 targeted before end of 2026.

Intensity Therapeutics (market cap ~$7.4M) resumed enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma trial in April 2026 after a March 2025 pause due to funding constraints; the trial had enrolled 21 patients during the pause. The company restarted patient treatment in Phase 2 INVINCIBLE-4 (triple negative breast cancer) in July 2026 after protocol modifications; preliminary data from 14 patients showed 71% pathological complete response in the INT230-6 arm vs. 42% in standard-of-care alone, with 44% fewer grade 3 adverse events. Cash position: $9.5M as of June 30, 2026; raised $1.6M net in Q2 2026 under a $60M ATM facility and additional $1.3M post-quarter.

On June 4, 2026, Imunon raised $10 million in gross proceeds: $2.5 million from 250 shares of non-redeemable, non-convertible preferred stock and $7.72 million from two secured promissory notes (principal amounts $2.72M at 8% and $5.0M at 5%, maturing 18 months from issuance). Phase 3 OVATION 3 trial for lead candidate IMNN-001 in ovarian cancer is enrolling faster than forecast; Phase 2 OVATION 2 showed 14.7-month median OS benefit (45.1 vs. 30.4 months vs. standard of care). H1 2026 net loss was $7.1M on $7.1M operating expenses; cash position as of June 30, 2026 was $6.9M.

LB Pharmaceuticals announced a $150 million private placement (completed July 2026) from new and existing institutional investors to expand LB-102 into additional neuropsychiatric indications. The company accelerated the pivotal Phase 3 NOVA-2 trial topline readout in acute schizophrenia to H1 2027 (from prior later guidance) due to faster-than-expected enrollment, with an FDA pre-NDA meeting planned for H2 2027. Cash position stood at $327.8M as of June 30, 2026, expected to fund operations beyond Q2 2029; R&D expenses surged to $44.1M in Q2 2026 from $2.4M in Q2 2025, driven primarily by Phase 3 trial costs ($32.1M increase).

Theriva Biologics initiated the VIRAGE2 Phase 2a trial dosing first patients with VCN-01 in metastatic pancreatic cancer, testing more frequent (≥3 doses ~2 months apart) versus prior 2-dose regimen; enrollment of 6 evaluable patients expected to complete H2 2026 with results by Q3 2027. Cash position: $11.3M as of June 30, 2026 (down $1.7M from Dec 31, 2025), with runway into Q1 2027; six-month net loss was $5.3M. Share count increased to 45.9M from 35.7M (28.6% dilution year-over-year).

TON Strategy Company (Nasdaq: TONX, market cap ~$6.8M) reported Q2 2026 revenue of $15.0M from Gram staking on holdings of 230.5M Gram units (fair value $369.5M as of June 30, 2026), up from $3.0M in Q1 2026. The company completed wind-down of legacy operations expected to eliminate ~$4.0M in annual cash operating costs. Terminated Kingsway Capital Partners advisory agreement on August 10, 2026, recording ~$2.9M noncash write-off; also recorded $5.5M noncash stock compensation charge from resolving legacy RSU issue.

Veradermics reported Q2 2026 results with positive Phase 2 data for VDPHL01 (oral minoxidil) in female pattern hair loss (Study 207: 22.7–23.3 hairs/cm² increase, 88.9–90% improvement at 6 months). Study 306 (556 female participants, registration-directed Phase 2/3) enrollment completed; topline data expected 1H27. Study 302 (male) and Study 304 (male, confirmatory Phase 3) expected to report 12-month and topline data respectively in 2H26. Cash position strengthened to $819.9M (June 30, 2026) following $472M capital raise in May 2026; company states funding extends to 2030 through Phase 3 readouts and potential commercial launch. Q2 2026 net loss was $23.5M (vs. $15.6M in Q2 2025); R&D expenses $18.6M (up $4.3M YoY), G&A $10.9M (up $9.2M YoY).

Energy Focus reported Q2 2026 net sales of $3.7M (228% YoY increase), driven by $1.5M commercial sales growth from new Australian customer ESS shipments and $1.1M military sales growth. However, gross margin fell to negative 6.8% from positive 12.9% YoY due to $424K inventory reserves. Net loss widened to $0.9M ($(0.14)/share) from $0.2M loss YoY. On May 29, 2026, the company raised $250K via private placement of 65,789 shares at $3.80/share with Euka Power Japan Co., Ltd., and took $911K in short-term borrowings, bringing cash flat at $1.1M despite $0.8M operating cash burn in H1 2026.

Adagio Medical (market cap ~$7M) submitted a Premarket Approval application to the FDA in May 2026 for its vCLAS Ventricular Ablation System, supported by FULCRUM-VT pivotal trial data (209 patients, 84% ICD shock freedom at 6 months, 2.4% major adverse events). Q2 2026 net loss was $6.7M ($0.30/share) on zero revenue, versus $3.9M loss in Q2 2025; cash declined from $17.1M (Dec 2025) to $7.7M (June 2026). The company paused European commercial activity and remains pre-revenue in the U.S.

KIDZ AI Inc. (market cap ~$3.3M) announced a 1-for-15 reverse stock split of its Class A and Class B common stock, effective August 13, 2026, approved by shareholders on June 10, 2026 and by the Board on July 21, 2026. The split is designed to increase per-share trading price and help the company maintain compliance with Nasdaq's minimum bid price listing requirement. No fractional shares will be issued; fractional shares will be rounded up to the nearest whole share.

SolarMax Technology (market cap ~$50.4M) effected a 1-for-12 reverse stock split effective August 13, 2026, reducing outstanding shares from 56.9M to ~4.7M. The split aims to restore the stock price above Nasdaq's $1 minimum bid requirement (deadline August 31, 2026) after the company fell below this threshold in March 2026. However, the company also faces a separate $35M minimum market value listing requirement (deadline December 21, 2026) that the reverse split does not address.

Erez Asset Management, holding ~4.7% of UMH Properties (one of the largest shareholders), sent a July 13, 2026 letter to the Board demanding a strategic review including potential sale. Erez estimates UMH's NAV at $21.25–$24.25/share (midpoint exceeds any closing price in past decade except COVID rally), versus recent trading ~$15/share. Erez claims the Board has rejected multiple strategic and financial buyer inquiries and threatens unspecified shareholder actions if the Board refuses engagement by July 20, 2026.

JBD Innovation Ltd. (14.4% owner, 315,361 shares) and Victor Tshuva & Co. (3.0% owner, 66,000 shares) executed a cooperation agreement on August 7, 2026, resolving a July 27 demand letter and August 2 court injunction against a private placement. Two departing directors (Ms. Lurie, Mr. Wagner) resign; four new directors (Avichay Vardi, Oz Adler, Gabriel Kabazo, Hila Karon Revach) join, expanding the board from 5 to 7 members. JBD simultaneously committed via side letter to provide up to $12 million in convertible debt financing over 24 months if the board determines funding is needed for operations.

On March 26, 2026, Vor Biopharma sold 5,338,078 shares of common stock to TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. for aggregate proceeds of $74,999,995.90 at $14.05 per share. The investors received registration rights to resell shares; Company must file registration statement within 30 days and achieve effectiveness within 60 days, with liquidated damages of 1% per 30-day blackout period (capped at 5% aggregate).

Microbot Medical announced Q2 2026 revenue more than doubled versus Q1 2026, driven by full market release of LIBERTY robotic system in April 2026 and adoption by new health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania (joining Georgia, Florida, New York from LMR phase). Company signed Lovell Government Services agreement for access to 2,000+ federal healthcare facilities, expanded sales territories from 4 to 8, entered manufacturing partnership with Sanmina for second production site, and received Israeli regulatory clearance—the first international approval for LIBERTY. No specific dollar amounts disclosed; concrete metrics are revenue growth >100% and customer/site/territory expansion.

Data I/O Corporation (market cap ~$26.9M) filed an S-1/A amendment on August 11, 2026, to register secondary shares for sale by existing stockholders: 869,840 outstanding common shares, 1,080,000 warrant shares (exercise of outstanding warrants), and 2,736,531 conversion shares (from Series B Convertible Preferred Stock issued June 17, 2026 upon conversion of convertible debentures). The selling stockholders acquired these securities in a private placement exempt from registration under Section 4(a)(2). This amendment adds only Exhibit 5.1 (legal opinion from Dorsey Whitney LLP confirming validity of shares); the core registration statement was filed July 31, 2026.

TherapeuticsMD reported Q2 2026 net income of $164K (down 70% YoY from $545K), with license revenue of $869K (down 9% from $952K in Q2 2025). Operating expenses rose 2.3% to $1.7M due to higher G&A and patent write-offs. Cash position stands at $9.2M as of June 30, 2026. The company continues evaluating strategic alternatives including acquisition, merger, asset sale, or other business combinations, with no timetable or commitment announced.